Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice

Cardiovascular Risk Markers and Mechanisms in Targeting the COX Pathway for Colorectal Cancer Prevention

(2011) J. A. Oates   Cancer Prevention Research

Emotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga

(2010) Tilo Grosser et al.   Annual Review of Medicine

Targeted Deletions of Cyclooxygenase-2 and Atherogenesis in Mice

(2010) Yiqun Hui et al.   CIRCULATION

Cause-Specific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals

(2010) Emil Loldrup Fosbøl et al.  

MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation

(2009) Andreas Koeberle et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Dual 12/15- and 5-Lipoxygenase Deficiency in Macrophages Alters Arachidonic Acid Metabolism and Attenuates Peritonitis and Atherosclerosis in ApoE Knock-out Mice

(2009) Daniel Poeckel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Leukotriene E4–induced pulmonary inflammation is mediated by the P2Y12receptor

(2009) Sailaja Paruchuri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function

(2009) D. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice

(2008) Richard Yang Cao et al.   ATHEROSCLEROSIS

Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials

(2008) Scott D. Solomon et al.   CIRCULATION

Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population

(2008) Luis Alberto García Rodríguez et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial

(2008) John A Baron et al.   LANCET